The OS of patients bearing CRC with high level of expression of SIGLEC6 or FCRL4 was 23.08 and 24.54 months, respectively, versus 91.04 and 91.30 months for patients bearing tumors with low expression levels (log-rank test, p=0.0033 and p=0.0303, respectively; Figures 3B, C). This evidence concerns the gene SIGLEC6 and colorectal carcinoma.